CAS NO: | 1818-71-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
20mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibitsFLT3andHDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML[1]. | ||||||||||||||||||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | Crotonoside (0-200 μM;) selectively inhibits the viability of AML cell line MV4-11, MOLM-13 (with FLT3-ITD mutant) and KG-1 (without FLT3-ITD mutant) in a dose-dependent manner with an IC50of 11.6 μM, 12.7 μM and 17.2 μM, respectively[1].Crotonoside (0-100μM; 7 hours) inhibits the phosphorylation of FLT3 Erk1/2, Akt/mTOR and STAT5 is strongly inhibited by crotonoside at higher concentration of 12.5 μM in a concentration-dependent manner[1].Crotonoside (0-100 μM; 12 hours) exhibits a dose-dependent increase in the percentage of G0/G1 phase and a dose-dependent decrease in the percentage of G2/M and S phases cells[1].Crotonoside (0-100 μM; 24 hours) leads to concentration-dependent changes in the number of apoptotic MV4-11 cells, results in a dose-dependent decrease in the level of pro-caspase-3 and a dose-dependent increase in the level of the cleaved caspase-3 fragments[1]. Cell Viability Assay[1]
Western Blot Analysis[1]
Cell Cycle Analysis[1]
Apoptosis Analysis[1]
| ||||||||||||||||||||||||||||||||
体内研究 (In Vivo) | Crotonoside(intraperitoneal and intravenous injection; 70 mg/kg, 35 mg/kg; once daily) induces a significant antitumor activity and inhibited xenograft tumor progress as compared to treatment with vehicle[1].
| ||||||||||||||||||||||||||||||||
分子量 | 283.24 | ||||||||||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||||||||||
Formula | C10H13N5O5 | ||||||||||||||||||||||||||||||||
CAS 号 | 1818-71-9 | ||||||||||||||||||||||||||||||||
中文名称 | 瑞加德松杂质17 | ||||||||||||||||||||||||||||||||
结构分类 |
| ||||||||||||||||||||||||||||||||
来源 |
| ||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(88.26 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|